Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Rating Lowered

Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday. Merrimack Pharmaceuticals Price Performance Shares of MACK stock traded down $0.08 during trading hours on Friday, reaching $11.80. 209,960 shares of the stock were exchanged, compared to its average volume of […]

Related Keywords

Massachusetts , United States , Cambridge , Cambridgeshire , United Kingdom , , Merrimack Pharmaceuticals , News Ratings For Merrimack Pharmaceuticals Daily , Boothbay Fund Management , Merrimack Pharmaceuticals Price Performance , Wittenberg Investment Management Inc , Merrimack Pharmaceuticals Inc , Hedge Funds Weigh In On Merrimack Pharmaceuticals , Free Report , Street Group , Street Corp , Investment Management , Fund Management , Madison Avenue Partners , Merrimack Pharmaceuticals Daily , Nasdaq Mack , Smack , Medical , 59032810 , Downgrade , Stocknews Com ,